Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Gains from Investment Securities (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Gains from Investment Securities for 8 consecutive years, with $2.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Investment Securities rose 106.93% to $2.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $830194.0, a 102.18% increase, with the full-year FY2025 number at $3.6 million, up 61109.53% from a year prior.
  • Gains from Investment Securities was $2.8 million for Q4 2025 at Outlook Therapeutics, down from $40.4 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $40.4 million in Q3 2025 to a low of -$40.3 million in Q4 2024.